louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06258278: Clinical Results of Arthroscopic-Assisted Lower Trapezius Tendon Transfer for Massive, Irreparable Rotator Cuff Tears
Official title: Clinical Results of Arthroscopic-Assisted Lower Trapezius Tendon Transfer for Massive, Irreparable Rotator Cuff Tears
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Massive Irreparable Rotator Cuff Tears
Keywords: Irreparable Rotator Cuff Tears
Tendon Transfer
Massive Rotator Cuff Tears
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2024-02-14
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aimed to describe a modified technique for arthroscopic-assisted transfer of the lower trapezius tendon in a selected group of patients with irreparable rotator cuff tears and to evaluate its short-term results.

Detailed description: Patients scheduled for surgery will undergo evaluation one day before the surgical procedure and again at the six-month postoperative mark. Pain intensity will be assessed using the Visual Analog Scale (VAS), while shoulder function will be evaluated using both the University of California, Los Angeles (UCLA) Shoulder Score and the Constant-Murley Shoulder Score.

Eligibility criteria: Inclusion Criteria:

* patients with massive, chronic (\>6 months), irreparable rotator cuff tears;
* patients with no concomitant irreparable subscapularis tears;
* patients who underwent a trial of at least 6-month period of conservative treatment with no benefit;
* patients with a stage 3 or greater degree of supraspinatus muscle fatty infiltration;

Exclusion Criteria:

* patients with glenohumeral arthritis;
* patients with adhesive capsulitis or passive joint motion restriction
* patients with neurologic deficits

Primary outcomes:
measure: Pain intensity
timeFrame: one day before surgery
measure: Pain intensity
timeFrame: 6 months after surgery
measure: Shoulder ability
timeFrame: one day before surgery
measure: Shoulder ability
timeFrame: 6 months after surgery
measure: Shoulder function
timeFrame: one day before surgery
measure: Shoulder function
timeFrame: 6 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University Hospital
Study officials:
affiliation: Gazi University
name: Ulunay Kanatlı
role: PRINCIPAL_INVESTIGATOR
affiliation: Gazi University
name: Furkan Aral
role: STUDY_CHAIR
References:
Clinical trial NCT06849778: An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis
Official title: A Phase 1, Open-label, Pharmacokinetic Study of TS-172 in Patients on Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Patients on Hemodialysis
Lead sponsor: Taisho Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-02-27
Enrollment: 7
Sex: MALE
Minimum age (years): 18
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase 1, open-label, pharmacokinetic study of TS-172 in patients on hemodialysis


Eligibility criteria: Inclusion Criteria:

1. Japanese male patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to the screening test
2. Patients aged \>= 18 and \< 75 years at the time of obtaining informed consent

Exclusion Criteria:

1. Patients with gastric or intestinal ulceration or a history of them within the past year prior to the date of initiation of treatment, or patients with inflammatory bowel disease or irritable bowel syndrome, or a history of these within the past 5 years prior to the date of initiation of treatment
2. Patients scheduled for renal transplantation, home hemodialysis or change of dialysis facility (transfer or temporary dialysis at other hospital) during the study period
3. Patients who frequently experience diarrhea (defined as Bristol Stool Scale score of 6 or higher)

Primary outcomes:
measure: Concentration of unchanged form in plasma
timeFrame: Day 1, 2, 8 and 9
measure: Concentration of major metabolites in plasma
timeFrame: Day 1, 2, 8 and 9
Secondary outcomes:
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Taisho Pharmaceutical Co., Ltd selected site
Study officials:
affiliation: Taisho Pharmaceutical Co., Ltd.
name: Taisho Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00794378: Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)
Official title: A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Allergic Rhinitis
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2008-11-20
Enrollment: 202
Sex: ALL
Minimum age (years): 6
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This study was conducted to compare the taste acceptability of Zyrtec syrup with desloratadine syrup in children. Children between 6 and 11 years of age received 5 mL of each syrup, separated by 15 to 20 minutes on a single day.

Detailed description: This study is a cross-over study design.

Eligibility criteria: Inclusion Criteria:

Subjects must be:

* Between 6 and 11 years of age in good general health
* Premenarcheal if female

Exclusion Criteria:

Subjects who:

* Have known allergies or sensitivities to either of the drug formulations
* Have a medical condition that may interfere with the subject's ability to discriminate between tastes
* Have used any antihistamines within 24 hours prior to dosing
* Were taking sedatives, tranquilizers, or monoamine oxidase inhibitor drugs
* Were involved in another clinical or market research study within the past 30 days

Primary outcomes:
measure: Taste acceptability as determined from smiley-face scale of 1 (frowning child) to 5 (happy child face).
timeFrame: During the only study visit
Secondary outcomes:
measure: Taste flavor preference between bubble-gum, banana-grape, or grape flavors
timeFrame: During the only study visit
measure: Adverse Events
timeFrame: During the only study visit
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05648578: The Effect of Reiki Application on Stress and Anxiety Levels
Official title: The Effect of Reiki Practice on Stress and Anxiety Levels in Nurses: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stress
Keywords: Anxiety
Nursing
Reiki
Perceived stress
Lead sponsor: Siirt University
Sponsor class: OTHER
First posted: 2022-12-13
Enrollment: 128
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of this study is to determine the effect of reiki practice on stress and anxiety levels in nurses.

Detailed description: It was a randomized controlled trial. Reiki was applied to the participants in the experimental group twice a week for two weeks. No intervention was applied to the participants in the control group.

Eligibility criteria: Inclusion Criteria:

* Volunteer nurses were included in the research

Exclusion Criteria:

* Nurses, who had previous reiki experience and did not agree to participate in the study, were excluded

Primary outcomes:
measure: Introductory Questionnaire
timeFrame: Baseline
measure: Perceived Stress Scale
timeFrame: Change from Baseline Stress at 2 week
measure: Beck Anxiety Inventory
timeFrame: Change from Baseline Anxiety at 2 week
Secondary outcomes:
Other outcomes:
Locations:
city: Siirt
country: Turkey
facility: Siirt University
Study officials:
References:
Clinical trial NCT00861978: St. John's Wort Extract LI 160 for the Treatment of Atypical Depression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Atypical Depression
Keywords: mild to moderate depression with atypical features according to DSM-IV
Lead sponsor: Cassella-med GmbH & Co. KG
Sponsor class: INDUSTRY
First posted: 2009-03-16
Enrollment: 201
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.

Detailed description: The general picture of depression is still that of the traditionally called endogenous type, which is also the form that was characterized extensively in clinical trials. Atypical depression with reversed vegetative signs, such as hyperphagia or hypersomnia, is traditionalla neglected, demonstrated by the fact that in the most widely used depression scales, such as the Hamilton Depression Scale, melancholic symptoms have a specific weight, while, by contrast, reversed vegetative signs are not included. This etablishes a tendency to underestimate the severity of atypical depression.

Eligibility criteria: Main Inclusion Criteria:

* Mild to moderate depression (ICD-10 F32.0, F32.1) with atypical features according to DSM-IV, lasting at least 3 months
* Female and male Caucasians aged 18 to 70 years
* At least one of HAMD-28 scale items 22-26 scores \>1

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06727578: Pleural Irrigation With a Novel Devise.
Official title: A Pilot Assessment of the Safety and Efficacy of Pleural Irrigation for Retained Pleural Infection Using a Novel Irrigation Device
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pleural Effusion Disorder
Lead sponsor: Beth Israel Deaconess Medical Center
Sponsor class: OTHER
First posted: 2024-12-11
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Single-arm pilot trial of the use of intrapleural saline irrigation to treat retained pleural infections for patients with contraindications to standard of care intrapleural enzymatic therapy.


Eligibility criteria: Inclusion Criteria:

* Retained pleural effusion identified via bedside ultrasound within the first 24 hours after chest tube insertion
* Patient is contraindicated from receiving intrapleural enzymatic therapy within the first 24 hours after chest tube insertion

Exclusion Criteria:

* Non-infectious cause of pleural fluid analysis findings listed above identified (e.g. malignancy)
* Post-procedural empyema or complicated parapneumonic effusion

Primary outcomes:
measure: Radiographic improvement (reduction in the ammount of pleural effusion messured in centimeters) by bed side ultrasound day 1,2,3,4,5.
timeFrame: Daily for 8 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Davies HE, Davies RJ, Davies CW; BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug;65 Suppl 2:ii41-53. doi: 10.1136/thx.2010.137000. No abstract available.
citation: Gupta I, Eid SM, Gillaspie EA, Broderick S, Shafiq M. Epidemiologic Trends in Pleural Infection. A Nationwide Analysis. Ann Am Thorac Soc. 2021 Mar;18(3):452-459. doi: 10.1513/AnnalsATS.202001-075OC.
citation: Sogaard M, Nielsen RB, Norgaard M, Kornum JB, Schonheyder HC, Thomsen RW. Incidence, length of stay, and prognosis of hospitalized patients with pleural empyema: a 15-year Danish nationwide cohort study. Chest. 2014 Jan;145(1):189-192. doi: 10.1378/chest.13-1912. No abstract available.
citation: Grijalva CG, Zhu Y, Nuorti JP, Griffin MR. Emergence of parapneumonic empyema in the USA. Thorax. 2011 Aug;66(8):663-8. doi: 10.1136/thx.2010.156406. Epub 2011 May 26.
citation: Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med. 1980 Oct;69(4):507-12. doi: 10.1016/0002-9343(80)90460-x.
Clinical trial NCT01566578: A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF
Official title: A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Plaque Psoriasis
Lead sponsor: Ennar Pharmaceuticals AF
Sponsor class: INDUSTRY
Collaborators: name: University of Zurich
First posted: 2012-03-29
Enrollment: 24
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Investigation of EGF-Receptor Downregulation by topical EGF (dermal cream) exposition.


Eligibility criteria: Inclusion Criteria:

* Informed consent
* Mild to moderate psoriasis (all types) with active plaques on both body sides accessible for biopsy and self product application
* EGFR immunohistochemistry score \> 5
* Male
* Age 18-60 years

Exclusion Criteria:

* Systemic psoriasis treatment 3 months prior and during the study
* Local psoriasis treatment on the investigational sites in the last 30 days or during the study
* Known hypersensitivity or allergy to the EGF containing product (Newskin) and/or to Vaseline/10% salicylic acid and/or to local anaesthetics of the amid type
* Known or suspected non-compliance to study protocol Coagulopathy or treatment with anticoagulants
* History of malignant disease Other clinically relevant concomitant disease state Participation in another investigational drug study in the last 30 days

Primary outcomes:
measure: Change from baseline in EGFR density in epidermis of psoriasis lesion
timeFrame: Day 66
Secondary outcomes:
measure: Change to baseline in target lesion severity score (PASI)
timeFrame: Day 80
measure: Change to baseline in histological feature: thickness of the epidermis
timeFrame: Day 66
measure: Number of participants with adverse events
timeFrame: Day 80
measure: Change to baseline in the histological feature: acanthosis
timeFrame: Day 66
measure: Change to baseline in histological feature: epidermal/dermal lymphocytic infiltrates
timeFrame: Day 66
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Dermatology Clinic
Study officials:
affiliation: University Hospital Zurich, Dermatology Clinic
name: Thomas Kündig, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01729078: Dietary Interventions in Prediabetes
Official title: The Effects of Dietary Supplementation on Hepatic Insulin Action and Glucose Tolerance in Pre-diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Impaired Fasting Glucose
Pre Diabetes
Liver Fat
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2012-11-20
Enrollment: 48
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Assessment of glucose metabolism and liver fat after 12 week dietary intervention in pre diabetes subjects. Subjects will be randomized to either high fat (olive oil supplemented),high carb/high fiber (beans supplemented) and high carb/low fiber diets. Glucose metabolism will be assessed by labeled oral glucose tolerance test and liver fat by magnetic resonance spectroscopy pre randomization and at 8 and 12 week after starting dietary intervention.


Eligibility criteria: Inclusion Criteria:

* Impaired fasting glucose(100-125 mg/dl)
* HbA1c 5.7-6.4 %
* BMI 26-40 kg/sq.m

Exclusion Criteria:

* MRS contraindication
* Pregnant women
* Liver disease

Primary outcomes:
measure: Changes in liver fat content after 12 weeks of intervention
timeFrame: 12 weeks
Secondary outcomes:
measure: Change in glucose metabolism after 12 weeks of intervention
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo clinic
state: Minnesota
Study officials:
References:
citation: Errazuriz I, Dube S, Slama M, Visentin R, Nayar S, O'Connor H, Cobelli C, Das SK, Basu A, Kremers WK, Port J, Basu R. Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes. J Clin Endocrinol Metab. 2017 May 1;102(5):1765-1774. doi: 10.1210/jc.2016-3722.
Clinical trial NCT00800371: Magnetic Resonance Imaging (MRI) in Asymptomatic Patients With Juvenile Idiopathic Arthritis (JIA)
Official title: Diagnostic Value of MRI and Ultrasound in Patients With JIA
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Juvenile Idiopathic Arthritis
Keywords: JIA
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2008-12-02
Enrollment: 20
Sex: ALL
Minimum age (years): 7
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with JIA

Brief summary: Juvenile idiopathic arthritis (JIA) may progress asymptomatically leading to joint destruction despite treatment.

The aim of the observational study is to describe patients with silent arthritis comparing symptoms, clinical findings with results of ultrasound and magnetic resonance imaging (MRI).


Eligibility criteria: Inclusion Criteria:

* children without symptoms or with only mild joints swelling or with only minimal limited range of motion

Exclusion Criteria:

* patients with manifest arthritis

Primary outcomes:
measure: Definition of patients with silent arthritis.
timeFrame: every three to six months from recruitment to end of study
Secondary outcomes:
measure: Comparison of diagnostic value of MRI and ultrasound.
timeFrame: every three to six months from recruitment to end of study
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: University Children's Hospital
state: Baden-Wuerttemberg
Study officials:
affiliation: University Hospital Tuebingen
name: Nikolay Tzaribachev, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01880671: Evaluation of a New Treatment for Migraine Attacks
Official title: Undersökning av ny Behandlingsmetod Vid migränanfall
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Migraine
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
First posted: 2013-06-19
Enrollment: 36
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of a novel therapy for treatment of migraine, pain reduction and relief of associated symptoms during ongoing migraine attacks, and presence of a preventive effect post treatment.


Eligibility criteria: Inclusion Criteria:

* Female or male subjects, in otherwise good health, 20 to 55 years of age
* Subjects who meet the ICHD-2 (2nd Edition of The International Headache Classification) criteria for migraine headache
* Subjects with a minimum of 1 migraine attack per month
* Attack duration of 4 to 72 hours
* Normal attack intensity of at least 4 on a 0-10 VAS-scale

Exclusion Criteria:

* Completed heart surgery
* Cardiovascular disease
* Vascular damage on neck vessels
* Disease other than migraine of the CSN
* Severe disease of vital body organs
* Severe psychiatric disorders
* More than 6 migraine attacks per month

Primary outcomes:
measure: Change from baseline in pain intensity according to VAS-scales (0-10)
timeFrame: Estimated 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Karolinska University Hospital, Huddinge
Study officials:
References:
citation: Juto JE, Hallin RG. Kinetic oscillation stimulation as treatment of acute migraine: a randomized, controlled pilot study. Headache. 2015 Jan;55(1):117-27. doi: 10.1111/head.12485. Epub 2014 Dec 29.
Clinical trial NCT00576771: Effects of Different Assisted Mechanical Ventilation in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilatory Assist (NAVA) and Controlled by Patient
Official title: Effects of Different Assisted Mechanical Ventilation in ALI/ARDS Patients: PSV, NAVA and Controlled by Patient
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: ALI/ARDS Patients
Lead sponsor: Policlinico Hospital
Sponsor class: OTHER
First posted: 2007-12-19
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators' aim is to study the effect of pressure support ventilation versus neurally adjusted assist (NAVA) and controlled by patient in mechanically ventilated ALI/ARDS subjects.

Detailed description: In this study, PSV is compared with NAVA and assisted mechanically ventilation controlled by patient through a button. Inclusion criteria are: assisted mechanically ventilated ALI/ARDS patients.

Eligibility criteria: Inclusion Criteria:

* ALI/ARDS patients

Exclusion Criteria:

* Haemodynamic instability
* Barotrauma
* COPD

Primary outcomes:
measure: Respiratory mechanics work of breathing,end expiratory lung volume, gas exchange, dead space, patient's comfort level
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Policlinico Hospital
Study officials:
affiliation: Policlinico Hospital
name: Davide Chiumello, MD
role: PRINCIPAL_INVESTIGATOR
References: